Diani E, Cecchetto R, Tonon E, Mantoan M, Lotti V, Lagni A
Microorganisms. 2025; 13(2).
PMID: 40005791
PMC: 11858464.
DOI: 10.3390/microorganisms13020426.
Duzgunes N, Fernandez-Fuentes N, Konopka K
Pathogens. 2021; 10(12).
PMID: 34959554
PMC: 8709411.
DOI: 10.3390/pathogens10121599.
Kemenesi G, Banyai K
Clin Microbiol Rev. 2018; 32(1).
PMID: 30541872
PMC: 6302355.
DOI: 10.1128/CMR.00106-17.
Klitting R, Roth L, Rey F, de Lamballerie X
Emerg Microbes Infect. 2018; 7(1):51.
PMID: 29593212
PMC: 5874243.
DOI: 10.1038/s41426-018-0053-x.
Bally M, Rydell G, Zahn R, Nasir W, Eggeling C, Breimer M
Angew Chem Int Ed Engl. 2012; 51(48):12020-4.
PMID: 23097253
PMC: 3546384.
DOI: 10.1002/anie.201205972.
The transmembrane domain sequence affects the structure and function of the Newcastle disease virus fusion protein.
Gravel K, McGinnes L, Reitter J, Morrison T
J Virol. 2011; 85(7):3486-97.
PMID: 21270151
PMC: 3067846.
DOI: 10.1128/JVI.02308-10.
Appraising the roles of CBLL1 and the ubiquitin/proteasome system for flavivirus entry and replication.
Fernandez-Garcia M, Meertens L, Bonazzi M, Cossart P, Arenzana-Seisdedos F, Amara A
J Virol. 2010; 85(6):2980-9.
PMID: 21191016
PMC: 3067953.
DOI: 10.1128/JVI.02483-10.
Small interference RNA profiling reveals the essential role of human membrane trafficking genes in mediating the infectious entry of dengue virus.
Ang F, Wong A, Ng M, Chu J
Virol J. 2010; 7:24.
PMID: 20122152
PMC: 2825209.
DOI: 10.1186/1743-422X-7-24.
Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody.
Sultana H, Foellmer H, Neelakanta G, Oliphant T, Engle M, Ledizet M
J Immunol. 2009; 183(1):650-60.
PMID: 19535627
PMC: 3690769.
DOI: 10.4049/jimmunol.0900093.
Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles.
Russell R, Kawaguchi K, Meunier J, Takikawa S, Faulk K, Bukh J
J Viral Hepat. 2009; 16(9):621-32.
PMID: 19302336
PMC: 2770242.
DOI: 10.1111/j.1365-2893.2009.01111.x.
Identification of novel target sites and an inhibitor of the dengue virus E protein.
Yennamalli R, Subbarao N, Kampmann T, McGeary R, Young P, Kobe B
J Comput Aided Mol Des. 2009; 23(6):333-41.
PMID: 19241120
DOI: 10.1007/s10822-009-9263-6.
Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans.
Foo C, Lou H, Whitbeck J, Ponce-de-Leon M, Atanasiu D, Eisenberg R
Virology. 2009; 385(2):368-82.
PMID: 19162289
PMC: 2693012.
DOI: 10.1016/j.virol.2008.12.019.
Closing the door on flaviviruses: entry as a target for antiviral drug design.
Perera R, Khaliq M, Kuhn R
Antiviral Res. 2008; 80(1):11-22.
PMID: 18585795
PMC: 2646114.
DOI: 10.1016/j.antiviral.2008.05.004.
Does Japanese encephalitis virus share the same cellular receptor with other mosquito-borne flaviviruses on the C6/36 mosquito cells?.
Ren J, Ding T, Zhang W, Song J, Ma W
Virol J. 2007; 4:83.
PMID: 17803826
PMC: 2075493.
DOI: 10.1186/1743-422X-4-83.
Solution structure of the envelope protein domain III of dengue-4 virus.
Volk D, Lee Y, Li X, Thiviyanathan V, Gromowski G, Li L
Virology. 2007; 364(1):147-54.
PMID: 17395234
PMC: 1950219.
DOI: 10.1016/j.virol.2007.02.023.
Thiol/disulfide exchange is required for membrane fusion directed by the Newcastle disease virus fusion protein.
Jain S, McGinnes L, Morrison T
J Virol. 2006; 81(5):2328-39.
PMID: 17151113
PMC: 1865930.
DOI: 10.1128/JVI.01940-06.
Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins.
Eschli B, Quirin K, Wepf A, Weber J, Zinkernagel R, Hengartner H
J Virol. 2006; 80(12):5897-907.
PMID: 16731928
PMC: 1472595.
DOI: 10.1128/JVI.00008-06.
Inhibition of receptor binding stabilizes Newcastle disease virus HN and F protein-containing complexes.
McGinnes L, Morrison T
J Virol. 2006; 80(6):2894-903.
PMID: 16501098
PMC: 1395434.
DOI: 10.1128/JVI.80.6.2894-2903.2006.
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry.
Tscherne D, Jones C, Evans M, Lindenbach B, McKeating J, Rice C
J Virol. 2006; 80(4):1734-41.
PMID: 16439530
PMC: 1367161.
DOI: 10.1128/JVI.80.4.1734-1741.2006.
Expanded tropism and altered activation of a retroviral glycoprotein resistant to an entry inhibitor peptide.
Amberg S, Netter R, Simmons G, Bates P
J Virol. 2005; 80(1):353-9.
PMID: 16352560
PMC: 1317511.
DOI: 10.1128/JVI.80.1.353-359.2006.